Nilotinib with Daridorexant Interaction Details
Brand Names Associated with Nilotinib
- Nilotinib
- Tasigna®
Brand Names Associated with Daridorexant
- Daridorexant
- QUVIVIQ®
Medical Content Editor Dr. Brian Staiger, PharmD
Last updated
Mar 07, 2024
Interaction Effect
Increased daridorexant and CYP3A4 substrate with NTI exposure
Interaction Summary
Concomitant use of daridorexant (CYP3A4 substrate) with a moderate CYP3A4 inhibitor which is also a CYP3A4 substrate with NTI as it increases exposure to daridorexant and CYP3A4 substrate with NTI, which may increase the risk of adverse reactions. If used concomitantly, use caution and do not exceed daridorexant dose of 25 mg once per night[1].
Severity
Major
Onset
Unspecified
Evidence
Probable
How To Manage Interaction
Concomitant use of daridorexant (CYP3A4 substrate) with a moderate CYP3A4 inhibitor which is also a CYP3A4 substrate with NTI as it increases exposure to daridorexant and CYP3A4 substrate with NTI, which may increase the risk of adverse reactions. If used concomitantly, use caution and do not exceed daridorexant dose of 25 mg once per night[1].
Mechanism Of Interaction
Inhibition of CYP3A4-mediated metabolism of daridorexant; inhibition of CYP3A4-substrate metabolism by daridorexant
Literature Reports
A) Concomitant use of daridorexant 25 mg and dilTIAZem (moderate CYP3A4 inhibitor) 240 mg increased daridorexant AUC by a geometric mean ratio (GMR) of 2.4 (90% CI, 2 to 2.8) and Cmax by a GMR of 1.4 (90% CI, 1.2 to 1.6) [1].
B) Concomitant use of single dose daridorexant 50 mg and midazolam (CYP3A4 substrate) 2 mg increased daridorexant AUC by a geometric mean ratio (GMR) of 1.4 (90% CI, 1.3 to 1.6) and Cmax by a GMR of 1.1 (90% CI, 1.0 to 1.3) [1].
References
1 ) Product Information: QUVIVIQ(R) oral tablets, daridorexant oral tablets. Idorsia Pharmaceuticals US Inc (per FDA), Radnor, PA, 2023.
Nilotinib Overview
-
Nilotinib is used to treat certain types of chronic myeloid leukemia (CML; a type of cancer of the white blood cells) who have recently found to have this condition in adults and children 1 year of age and older. It is also used to treat certain types of CML in adults whose disease could not be treated successfully with imatinib (Gleevec) or adults who cannot take imatinib because of side effects. Nilotinib is also used to treat certain types of CML in children 1 year of age or older whose disease could not be treated successfully with other tyrosine kinase inhibitor therapies or who cannot take these medications because of side effects. Nilotinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.
Daridorexant Overview
-
Daridorexant is used to treat insomnia (difficulty falling asleep or staying asleep). Daridorexant is in a class of medications called orexin receptor antagonists. It works by blocking the action of a certain natural substance in the brain that causes wakefulness.
Return To Our Drug Interaction Homepage
Feedback, Question Or Comment About This Information?
Ask Dr. Brian Staiger, PharmD, our medical editor, directly! He's always more than happy to assist.
Definitions
Severity Categories
Contraindicated
These drugs, generally, should not be used together simultaneously due to the high risk of severe adverse effects. Combining these medications can lead to dangerous health outcomes and should be strictly avoided unless otherwise instructed by your provider.
Major
This interaction could result in very serious and potentially life-threatening consequences. If you are taking this drug combination, it is very important to be under close medical supervision to minimize severe side effects and ensure your safety. It may be necessary to change a medication or dosage to prevent harm.
Moderate
This interaction has the potential to worsen your medical condition or alter the effectiveness of your treatment. It's important that you are monitored closely and you potentially may need to make adjustments in your treatment plan or drug dosage to maintain optimal health.
Minor
While this interaction is unlikely to cause significant problems, it could intensify side effects or reduce the effectiveness of one or both medications. Monitoring for changes in symptoms and your condition is recommended, and adjustments may be made if needed to manage any increased or more pronounced side effects.
Onset
Rapid: Onset of drug interaction typically occurs within 24 hours of co-administration.
Delayed: Onset of drug interaction typically occurs more than 24 hours after co-administration.
Evidence
Level of documentation of the interaction.
Established: The interaction is documented and substantiated in peer-reviewed medical literature.
Theoretical: This interaction is not fully supported by current medical evidence or well-documented sources, but it is based on known drug mechanisms, drug effects, and other relevant information.
How To Manage The Interaction
Provides a detailed discussion on how patients and clinicians can approach the identified drug interaction as well as offers guidance on what to expect and strategies to potentially mitigate the effects of the interaction. This may include recommendations on adjusting medication dosages, altering the timing of drug administration, or closely monitoring for specific symptoms.
It's important to note that all medical situations are unique, and management approaches should be tailored to individual circumstances. Patients should always consult their healthcare provider for personalized advice and guidance on managing drug interactions effectively.
Mechanism Of Interaction
The theorized or clinically determined reason (i.e., mechanism) why the drug-drug interaction occurs.
Disclaimer: The information provided on this page is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional regarding your specific circumstances and medical conditions.
Where Does Our Information Come From?
Information for our drug interactions is compiled from several drug compendia, including:
The prescribing information for each drug, as published on DailyMED, is also used.
Individual drug-drug interaction detail pages contain references specific to that interaction. You can click on the reference number within brackets '[]' to see what reference was utilized.
The information posted is fact-checked by HelloPharmacist clinicians and reviewed quarterly.